# Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions

Study · id `cardio:ct-nct02542007` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02542007](<https://clinicaltrials.gov/study/NCT02542007>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02542007

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 440 participants.

## Technical summary

Registry record NCT02542007. Randomized; no masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2017-05-27 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 440 participants (enrolled count; ClinicalTrials.gov record NCT02542007, source copy `cardio:ctgov-nct02542007-2021-09-09`, retrieved 2026-10-26)
- Start date: 2015-05 (registry gives no type) (ClinicalTrials.gov record NCT02542007, source copy `cardio:ctgov-nct02542007-2021-09-09`, retrieved 2026-10-26)
- Primary completion: 2017-05-27 (actual) (ClinicalTrials.gov record NCT02542007, source copy `cardio:ctgov-nct02542007-2021-09-09`, retrieved 2026-10-26)
- Completion: 2021-06-10 (actual) (ClinicalTrials.gov record NCT02542007, source copy `cardio:ctgov-nct02542007-2021-09-09`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02542007, source copy `cardio:ctgov-nct02542007-2021-09-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02542007-2021-09-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions
- Acronym: RECOVERY
- Condition: Coronary Arteriosclerosis
- Intervention (Device): OrbusNeich Combo stent™
- Intervention (Device): sirolimus-eluting stent system
- Lead sponsor: OrbusNeich
- Lead sponsor class: INDUSTRY
- Collaborator: CCRF Inc., Beijing, China
- Collaborator class: INDUSTRY
- Collaborator: OrbusNeich Medical (Shenzhen), Co. Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: OrbusNeich (`cardio:org-orbusneich`)
- Registry lists this organization as a collaborator: CCRF Inc., Beijing, China (`cardio:org-ccrf-inc-beijing-china`)

## Provenance

Content hash: a272d62ae85fe9e5c274a70b13228c75dcdf5d572bbb8908c32edc9d4df2f15e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
